TABLE 1.
Clinicopathological baseline characteristics of breast cancer patients–breast cancer cohort Guinea
| Characteristics | All cases |
|---|---|
| Age (mean, range) | 47.5 (16–85) |
| Sex n (%) | |
| Male | 4 (1.9) |
| Female | 206 (98.1) |
| Body mass index (mean, range) | 25.7 (14.9–38.7) |
| Comorbidities n (%) | |
| Yes | 50 (23.8) |
| No | 160 (76.2) |
| Inflammatory tumor n (%) | |
| Yes | 53 (25.3) |
| No | 157 (74.7) |
| Histology n (%) | |
| Invasive ductal carcinoma | 151 (71.9) |
| Invasive lobular carcinoma | 11 (5.2) |
| Carcinoma no other specified | 35 (16.7) |
| Sarcoma | 1 (0.5) |
| Other carcinomas | 12 (5.7) |
| Scarff Bloom Richardson (SBR) grade n (%) | |
| SBR I | 6 (2.9) |
| SBR II | 65 (31.0) |
| SBR III | 26 (12.4) |
| Missing | 113 (53.8) |
| Molecular profile n (%) | |
| ER/PR+/Her2− | 15 (7.1) |
| ER/PR+//Her2+ | 5 (2.4) |
| Her2+ | 9 (4.3) |
| ER/PR−/Her2− | 13 (6.3) |
| Missing | 168 (80.0) |
| Stage n (%) | |
| Stage I | 13 (6.2) |
| Stage II | 45 (21.4) |
| Stage III | 152 (72.4) |
| Type of surgery n (%) | |
| Conservative | 25 (11.9%) |
| Radical | 185 (88.1%) |
| Chemotherapy (CT) n (%) | |
| Yes | 205 (97.6) |
| No | 5 (2.4) |
| Neoadjuvant CT | 149 (72.7) |
| Adjuvant CT | 131 (63.9) |
| Neoadjuvant + adjuvant CT | 85 (41.5) |
| Radiotherapy n (%) | |
| Yes | 90 (42.9) |
| No | 120 (57.1) |